Semaglutide and cardiovascular risk
In the SELECT trial, the GLP-1 receptor–agonist peptide semaglutide was associated with fewer major cardiovascular events in adults with obesity and existing heart disease but not diabetes.
What the study found
SELECT (New England Journal of Medicine, 2023) was a randomized trial of once-weekly semaglutide, an engineered GLP-1 receptor–agonist peptide, in adults who had overweight or obesity and established cardiovascular disease but did not have diabetes. Over several years, participants assigned to semaglutide had a lower rate of major adverse cardiovascular events — a composite of cardiovascular death, heart attack, and stroke — than those assigned to placebo. This describes what the trial measured; it is not advice, and nothing here recommends any medicine.
Why it matters
Earlier work established that GLP-1 peptides lower blood sugar and body weight. SELECT asked a different question: whether the drug changes hard cardiovascular outcomes in people without diabetes. Because it studied a large population defined by weight and heart disease rather than blood sugar, it pointed toward a broader role for this peptide class beyond glucose control.
Analysis — the peptide pattern
This fits an unfolding pattern (analysis, not a single-study claim): long-acting engineered peptides derived from gut hormones keep showing effects that reach past their original target, from weight to the cardiovascular system. The signal researchers are watching is whether the benefit comes mainly from weight loss or from additional direct effects — an open, still-evolving question.
What is still uncertain
Trials report averages, not individual results. Gastrointestinal side effects are common, the cardiovascular benefit's mechanism is not settled, effects when treatment stops are still being studied, and long-term safety and the best candidates remain under investigation.